New Jersey Law Journal (reprinted with permission)
This article published by the New Jersey Law Journal, co-authored by Michael F. Schaff, Co-Chair of the Corporate, Health, and Cannabis law practice groups, is an in-depth statutory and regulatory review of the "Psilocybin Behavioral Health Access and Services Act” (S. 2934), a bill introduced by New Jersey Senate President Nicholas Scutari.
*Cannabis Law Disclaimer: Per federal law, under the Controlled Substances Act, marijuana is categorized as a Schedule I controlled substance. Possession, use, distribution, and/or sale of cannabis is a Federal crime and is subject to related Federal policy, regardless of any state law that may authorize certain marijuana activity. Compliance with state marijuana law does not equal compliance with federal law. Legal advice provided by Wilentz, Goldman & Spitzer, P.A. is designed to counsel clients regarding the validity, scope, meaning, and application of existing and/or proposed cannabis law. Wilentz, Goldman & Spitzer, P.A. will not provide guidance or assistance in circumventing or violating Federal or state cannabis law or policy, and any advice provided by Wilentz, Goldman & Spitzer, P.A. should not be construed as such.